Novartis AG (NVS) states Rare Muscle Disease Drug Shows Promise in Early Trial

Novartis AG (NYSE:NVS) is among the Best Pharmaceutical Stocks. On June 11, Novartis AG (NYSE:NVS) reported that an ...
La Grande Observer

Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated ...
Seeking Alpha

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ...
Nasdaq

Avidity Biosciences Announces Changes to its Board of Directors

LA JOLLA, Calif., Jan. 11, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody ...
The Motley Fool

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Novartis is acquiring Avidity to enhance its developmental pipeline by leveraging Avidity's expertise in a class of ribonucleic acid (RNA) therapeutics known as antibody oligonucleotide conjugates ...
Times of San Diego

Stock Offering for RNA Specialist Avidity Biosciences Raises $461 Million

Avidity Biosciences, a Torrey Pines biopharmaceutical company, has closed its underwritten public offering of 12.13 million shares of common stock. That includes 1.58 million shares sold pursuant to ...
AOL

Why Avidity Biosciences Stock Blasted 42% Higher Today

The purchasing party is global pharmaceutical companyNovartis, which on Sunday divulged that it and Avidity had agreed to the acquisition. Under its terms, Switzerland-based Novartis will pay $72 per ...

Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth

Novartis (SWX:NOVN) reported breakthrough Phase III results for Rhapsido (remibrutinib) in chronic inducible urticaria, with ...
Nasdaq

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Benzinga.com

Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial

Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular ...
Seeking Alpha

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET "This World FSHD Day, we are excited to be joining ...
Yahoo Finance

Novartis to acquire Avidity Biosciences for about $12 billion

(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments ...